Genetic Testing: When should you consider testing beyond BRCA?

Collecting quantification and characterization data of biologics often requires a large amount of protein and multiple instruments. In this webinar, see how Lunatic makes batch-wise concentration measurements a breeze by using just 2 µL of sample and eliminating dilution steps and cross-contamination risks. Measure up to 96 samples in just 5 minutes, even at high concentrations. Want to take your protein quant up a notch? Stunner merges all the cool things Lunatic can do with DLS on a single platform. Along with concentration, Stunner enables you to measure the expected size and polydispersity, and aggregation propensity of your proteins in one shot. We will also discuss how you can create your own applications on Stunner to customize the data output the way you want.

In this webinar, Dr. Couch will present results from a recent study of multigene hereditary cancer panel testing in >10,000 women with triple-negative breast cancer (TNBC), focusing on the prevalence of cancer gene mutations among TNBC cases along with gene-specific associations with TNBC among Caucasians and African Americans. Clinical implications of these findings will also be discussed.

Autologous cell therapy products are patient-specific therapies that use cells harvested from a single patient to treat that same patient. Final product release tests that require minimal sampling, produce rapid valid results, and are inexpensive to use is critical because each lot of final product requires testing prior to implantation in the patient.

Single B cell screening is a powerful and efficient strategy for generating antigen-specific monoclonal antibodies.